Cargando…

CAR-T cells and BiTEs in solid tumors: challenges and perspectives

Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for their develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edeline, Julien, Houot, Roch, Marabelle, Aurélien, Alcantara, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054411/ https://www.ncbi.nlm.nih.gov/pubmed/33874996 http://dx.doi.org/10.1186/s13045-021-01067-5

Ejemplares similares

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
por: Allen, Cecily, et al.
Publicado: (2021)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
por: Kujawski, Maciej, et al.
Publicado: (2019)

BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
por: Huang, Shi‐Wei, et al.
Publicado: (2023)

Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
por: Deak, Dalma, et al.
Publicado: (2019)

TEs or not TEs? That is the evolutionary question
por: Vaknin, Keren, et al.
Publicado: (2009)

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)
por: Gauci, Marie-Léa, et al.
Publicado: (2021)

CAR T cells in solid tumors: challenges and opportunities
por: Marofi, Faroogh, et al.
Publicado: (2021)

Born to survive: how cancer cells resist CAR T cell therapy
por: Lemoine, Jean, et al.
Publicado: (2021)

Perspective: Disentangling the effects of tES on neurovascular unit
por: Arora, Yashika, et al.
Publicado: (2023)

CAR-T Therapies in Solid Tumors: Opportunities and Challenges
por: Guzman, Grace, et al.
Publicado: (2023)

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
por: Alcantara, Marion, et al.
Publicado: (2020)

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
por: Chen, Qiuqiang, et al.
Publicado: (2022)

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
por: Kegyes, David, et al.
Publicado: (2022)

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021)

CAR-T cells: Early successes in blood cancer and challenges in solid tumors
por: Dana, Hassan, et al.
Publicado: (2021)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
por: Xia, An-Liang, et al.
Publicado: (2017)

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
por: Guedan, Sonia, et al.
Publicado: (2018)

Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)
por: Zhong, Liqiang, et al.
Publicado: (2023)

The serodiagnostic potential of recombinant proteins TES–30 and TES–120 in an indirect ELISA in the diagnosis of toxocariasis in cattle, horses, and sheep
por: dos Santos, Lucas Moreira, et al.
Publicado: (2019)

First sensitivity limits of the ALPS TES detector
por: Dreyling-Eschweiler, Jan
Publicado: (2014)

Focal plane with phased arrays TES (20')
por: O'Brient, Roger
Publicado: (2016)

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
por: Yan, Ting, et al.
Publicado: (2023)

Making CAR T Cells a Solid Option for Solid Tumors
por: Schmidts, Andrea, et al.
Publicado: (2018)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

CAR T Cell Locomotion in Solid Tumor Microenvironment
por: Nguyen, Duy T., et al.
Publicado: (2022)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy
por: Maruta, Masaki, et al.
Publicado: (2019)

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma
por: Zheng, Meijun, et al.
Publicado: (2020)

TES functions as a Mena-dependent tumor suppressor in gastric cancer carcinogenesis and metastasis
por: Wang, Dan-dan, et al.
Publicado: (2019)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
por: Maalej, Karama Makni, et al.
Publicado: (2023)

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
por: Daei Sorkhabi, Amin, et al.
Publicado: (2023)

The tumor vasculature an attractive CAR T cell target in solid tumors
por: Akbari, Parvin, et al.
Publicado: (2019)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

New Strategies for the Treatment of Solid Tumors with CAR-T Cells
por: Zhang, Hao, et al.
Publicado: (2016)

CAR-T cells: the long and winding road to solid tumors
por: D’Aloia, Maria Michela, et al.
Publicado: (2018)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Hurdles to breakthrough in CAR T cell therapy of solid tumors
por: Marofi, Faroogh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_80dbi9j3brtt66p04mp7n2t1fr